Genomma Lab Internacional SAB de CV - Company Profile
Powered by 
All the data and insights you need on Genomma Lab Internacional SAB de CV in one report.
$295
- Save hours of research time and resources with
our up-to-date Genomma Lab Internacional SAB de CV Strategy Report
- Understand Genomma Lab Internacional SAB de CV position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Genomma Lab Internacional SAB de CV (Genomma Lab) carries out research, manufacturing, and commercialization of pharmaceuticals and other healthcare products. The company offers various products such as wellness products, personal care products, dermo-cosmetic products, and other healthcare products. It offers anti-acne products, scar removal ointments, anti-acids, varicose vein treatments, analgesics, anti-fungal products, anti-inflammatory products, multivitamins, stress management products, osteoarthritis treatments, and other products. Genomma Lab markets products under Suerox, Alliviax, Cicatricure, XL3, Tio Nacho, Lomecan, Nikzon, Novamil, Bio Electrico, Silka Medic, and SistemoGB. The company has business presence in the US, Mexico, Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Paraguay, Peru, Uruguay, and the Dominican Republic. Genomma Lab is headquartered at the Mexico City, Mexico.
Headquarters
Mexico
Address
Edificio Samara, Antonio Dovali Jaime No. 70 Piso 2, Colonia Santa Fe, Alvaro Obregon, 01210
Website
www.genommalab.com
Telephone
52 55 50810000
No of Employees
1,783
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LABB (MXK)
Revenue (2023)
$928.7M
-2.1%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
-25.8%
(2023 vs 2022)
Market Cap*
$913.9M
Net Profit Margin (2023)
XYZ
-24.2%
(2023 vs 2022)
* As of and is in US$
Genomma Lab Internacional SAB de CV premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Over the Counter Products | Suerox |
| Personal Care Products | Alliviax |
| Dermo-Cosmetics | Cicatricure |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In November, the company and Procaps Group entered into a partnership to develop, manufacture and market five Softgel products within Latin America. |
| 2023 | Regulatory Approval | In August, the company secured an approval of the sanitary license from the Mexican Ministry of Health's Federal Committee for protection from sanitary risks for the oral liquids, topical liquids and tablet coatings operations at Medicinas y Medicamentos Nacionales manufacturing facility in the State of Mexico. |
| 2023 | Financing Agreements | In January, the company secured US$60 million multi-currency long-term loan from IFC. |
Competitor Comparison
| Key Parameters | Genomma Lab Internacional SAB de CV | Medica Sur SAB de CV | Abbott Laboratories de Mexico SA de CV | Alcon Laboratorios SA de CV | AstraZeneca SA De CV |
|---|---|---|---|---|---|
| Headquarters | Mexico | Mexico | Mexico | Mexico | Mexico |
| City | Alvaro Obregon | Tlalpan | Mexico City | Mexico City | Tlalpan |
| State/Province | - | - | Distrito Federal | Distrito Federal | Distrito Federal |
| No. of Employees | 1,783 | 2,016 | - | - | - |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Rodrigo Alonso Herrera Aspra | Chairman | Executive Board | - | - |
| Marco Sparvieri | Chief Executive Officer | Senior Management | 2023 | - |
| Antonio Zamora Galland | Chief Financial Officer; Executive Vice President | Senior Management | 2015 | - |
| Alejandro Baston Patino | Executive Vice President - Business Expansion and Human Capital | Senior Management | 2007 | - |
| Jorge Luis Brake Valderrama | Vice Chairman | Executive Board | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward